Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Phase I trial of RV3-BB rotavirus vaccine: a human neonatal rotavirus vaccine.

Vaccine - 28 May 2013

Danchin M, Kirkwood C D, Lee K J, Bishop R F, Watts E, Justice F A, Clifford V, Cowley D, Buttery J P, Bines J E

Abstract excerpt

INTRODUCTION: RV3 is a human neonatal rotavirus strain (G3P[6]) that has been associated with asymptomatic neonatal infection and replicates well in the infant gut. RV3-BB rotavirus vaccine has been developed as a rotavirus vaccine candidate for administration at birth. METHODS: A single-centre, double-blind, randomised placebo-controlled Phase I study evaluated the safety and tolerability of a single oral dose...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Administration, Oral
Share to Antibodies, Anti-Idiotypic

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Antibodies, Neutralizing

Share to Double-Blind Method

Share to Immunoglobulin A

Share to Rotavirus Infections

Share to Rotavirus Vaccines

Share to Vaccines, Attenuated

Source

Identifiers

PMID: 23597719
DOI: 10.1016/j.vaccine.2013.04.008

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Phase I trial of RV3-BB rotavirus vaccine: a human neonatal rotavirus vaccine.PMID 23597719Read ↗

Serological responses to rotavirus NSP2 following administration of RV3-BB human neonatal rotavirus vaccine.Semantic proximity Read ↗

Molecular characterisation of rotavirus strains detected during a clinical trial of the human neonatal rotavirus vaccine (RV3-BB) in Indonesia.Semantic proximity Read ↗

Vaccine Take of RV3-BB Rotavirus Vaccine Observed in Indonesian Infants Regardless of HBGA Status.Semantic proximity Read ↗

Human Neonatal Rotavirus Vaccine (RV3-BB) Produces Vaccine Take Irrespective of Histo-Blood Group Antigen StatusSemantic proximity Read ↗

Human rotavirus vaccine Rotarix™ provides protection against diverse circulating rotavirus strains in African infants: a randomized controlled trial.Semantic proximity Read ↗

Rotavirus vaccines: targeting the developing world.Semantic proximity Read ↗

Multivalent Rotavirus Vaccine and Wild-type Rotavirus Strain Shedding in Australian Infants: A Birth Cohort Study.Semantic proximity Read ↗

Mucosal and systemic neutralizing antibodies to norovirus and rotavirus by oral immunization with recombinant rotavirus in infant miceSemantic proximity Read ↗

Rotarix®: vaccine performance 6 years postlicensure.Semantic proximity Read ↗

Mucosal and systemic neutralizing antibodies to norovirus induced in infant mice orally inoculated with recombinant rotavirusesSemantic proximity Read ↗

Generation of Recombinant Rotaviruses Expressing Human Norovirus Capsid ProteinsSemantic proximity Read ↗

Shedding of oral pentavalent bovine-human reassortant rotavirus vaccine indicates high uptake rate of vaccine and prominence of G-type G1.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.